A Randomised Controlled Non-inferiority Trial to Compare the Efficacy of 'HPV Screen, Triage and Treat' with 'HPV Screen and Treat' Approach for Cervical Cancer Prevention Among Women Living with HIV

Overview

Journal Nat Commun

Specialty Biology

Date 2025 Feb 22

PMID 39987163

Authors

Smita Joshi

Richard Muwonge

Ramesh Bhosale

Pritam Chaudhari

Vinay Kulkarni

Mahesh Mandolkar

Kedar Deodhar

Seema Kand

Nikhil Phadke

Shobini Rajan

B Kishore Kumar

Rengaswamy Sankaranarayanan

Partha Basu

Affiliations

Soon will be listed here.

Abstract

We report results of a randomized controlled trial to compare 'HPV screen and treat' (Arm 1) and 'HPV screen, triage and treat' (Arm 2) in women living with HIV (WLHIV), using visual inspection with acetic acid (VIA) as the triaging test. Treatment was offered to all HPV-positive women in Arm 1 and to VIA-positive women in Arm 2 with either thermal ablation or large loop excision. All women underwent a repeat HPV test one year after randomization. The primary outcome was non-inferiority of HPV clearance of Arm 2 at one-year follow up when compared to Arm 1. Of 544 HPV-positive consenting WLHIV, 433 were randomised in a 1:1 ratio to trial arms. At baseline, CIN 2/3 lesions were detected in 16.7% and 13.3% women in Arm 1 and Arm 2 respectively. HPV clearance was observed in 56.6% (95%CI 48.9-64.1) women in Arm 1 and 41.4% (95%CI 34.3-48.7) women in Arm 2 at follow-up in the intention-to-treat population (P = 0.004). 'HPV screen, VIA triage and treat' strategy was non-inferior to the 'screen and treat' strategy as the lower bound of the 95% confidence interval from the regression model was greater than 0.49 in both intention-to-treat analysis (RR 0.73, 95%CI 0.59-0.91) and per-protocol analysis (RR 0.74, 95%CI 0.60-0.93) according to the pre-specified analysis plan. Clinical trial registration: CTRI/2020/02/023349.

References

Kelly H, Weiss H, Benavente Y, de Sanjose S, Mayaud P . Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2017; 5(1):e45-e58. PMC: 5757426. DOI: 10.1016/S2352-3018(17)30149-2. View

Reimers L, Sotardi S, Daniel D, Chiu L, Van Arsdale A, Wieland D . Outcomes after an excisional procedure for cervical intraepithelial neoplasia in HIV-infected women. Gynecol Oncol. 2010; 119(1):92-7. PMC: 3089021. DOI: 10.1016/j.ygyno.2010.06.012. View

Looker K, Ronn M, Brock P, Brisson M, Drolet M, Mayaud P . Evidence of synergistic relationships between HIV and Human Papillomavirus (HPV): systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status. J Int AIDS Soc. 2018; 21(6):e25110. PMC: 5989783. DOI: 10.1002/jia2.25110. View

. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41(RR-17):1-19. View

Massad L, Xie X, DSouza G, Darragh T, Minkoff H, Wright R . Incidence of cervical precancers among HIV-seropositive women. Am J Obstet Gynecol. 2014; 212(5):606.e1-8. PMC: 4416973. DOI: 10.1016/j.ajog.2014.12.003. View

Kuhn L, Wang C, Tsai W, Wright T, Denny L . Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. AIDS. 2010; 24(16):2553-61. DOI: 10.1097/QAD.0b013e32833e163e. View

Hall M, Simms K, Murray J, Keane A, Nguyen D, Caruana M . Benefits and harms of cervical screening, triage and treatment strategies in women living with HIV. Nat Med. 2023; 29(12):3059-3066. PMC: 10719091. DOI: 10.1038/s41591-023-02601-3. View

Chung M, De Vuyst H, Greene S, Mugo N, Querec T, Nyongesa-Malava E . Human Papillomavirus Persistence and Association With Recurrent Cervical Intraepithelial Neoplasia After Cryotherapy vs Loop Electrosurgical Excision Procedure Among HIV-Positive Women: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2021; 7(10):1514-1520. PMC: 8343498. DOI: 10.1001/jamaoncol.2021.2683. View

Shmakova A, Germini D, Vassetzky Y . HIV-1, HAART and cancer: A complex relationship. Int J Cancer. 2019; 146(10):2666-2679. DOI: 10.1002/ijc.32730. View

10.

Zhao X, Liu Z, Zhao S, Hu S, Muwonge R, Duan X . Efficacy of point-of-care thermal ablation among high-risk human papillomavirus positive women in China. Int J Cancer. 2020; 148(6):1419-1427. DOI: 10.1002/ijc.33290. View

11.

Cuzick J, Clavel C, Petry K, Meijer C, Hoyer H, Ratnam S . Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006; 119(5):1095-101. DOI: 10.1002/ijc.21955. View

12.

Denny L, Saidu R, Boa R, Mbatani N, Castor D, Moodley J . Point-of-care testing with Xpert HPV for single-visit, screen-and-treat for cervical cancer prevention: a demonstration study in South Africa. Sci Rep. 2023; 13(1):16182. PMC: 10533854. DOI: 10.1038/s41598-023-43467-2. View

13.

Joshi S, Muwonge R, Kulkarni V, Mandolkar M, Lucas E, Pujari S . Can we increase the cervical cancer screening interval with an HPV test for women living with HIV? Results of a cohort study from Maharashtra, India. Int J Cancer. 2022; 152(2):249-258. DOI: 10.1002/ijc.34221. View

14.

Stelzle D, Tanaka L, Lee K, Ibrahim Khalil A, Baussano I, Shah A . Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2020; 9(2):e161-e169. PMC: 7815633. DOI: 10.1016/S2214-109X(20)30459-9. View

15.

Joshi S, Muwonge R, Kulkarni V, Lucas E, Kulkarni S, Kand S . Mobile Screening Unit (MSU) for the Implementation of the 'Screen and Treat' Programme for Cervical Cancer Prevention In Pune, India. Asian Pac J Cancer Prev. 2021; 22(2):413-418. PMC: 8190336. DOI: 10.31557/APJCP.2021.22.2.413. View

16.

McClung N, Mathoma A, Gargano J, Nyepetsi N, Querec T, Onyekwuluje J . HPV prevalence among young adult women living with and without HIV in Botswana for future HPV vaccine impact monitoring. BMC Infect Dis. 2022; 22(1):176. PMC: 8862300. DOI: 10.1186/s12879-022-07130-x. View

17.

Tainio K, Athanasiou A, Tikkinen K, Aaltonen R, Cardenas J, Hernandes . Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ. 2018; 360:k499. PMC: 5826010. DOI: 10.1136/bmj.k499. View

18.

Myers K, Ahmed N . The Role of HIV in the Progression through the Stages of the Human Papillomavirus to Cervical Cancer Pathway. AIDS Rev. 2018; 20(2):94-1043. DOI: 10.24875/AIDSRev.M18000021. View

19.

Sankaranarayanan R, Nene B, Shastri S, Jayant K, Muwonge R, Budukh A . HPV screening for cervical cancer in rural India. N Engl J Med. 2009; 360(14):1385-94. DOI: 10.1056/NEJMoa0808516. View

20.

Greene S, De Vuyst H, John-Stewart G, Richardson B, McGrath C, Marson K . Effect of Cryotherapy vs Loop Electrosurgical Excision Procedure on Cervical Disease Recurrence Among Women With HIV and High-Grade Cervical Lesions in Kenya: A Randomized Clinical Trial. JAMA. 2019; 322(16):1570-1579. PMC: 6806442. DOI: 10.1001/jama.2019.14969. View